Martine A. Rothblatt, Chairperson and CEO, has filed 2,346 Form 4 trades across two companies, with a heavy sell bias. The total value of open-market sales is roughly $1.003 billion, against just $863,947 in open-market purchases. The most recent activity, all on November 4, 2026, consists of 24 open-market sales in United Therapeutics (UTHR), ranging from $22,647 to $758,320, with a combined value of about $5.4 million. That same day, one option exercise (code M) was recorded at $1,118,720, which is a mechanical transaction and not a discretionary buy.
The pattern is consistent with a long-term disposition strategy rather than a shift in conviction. Rothblatt has not made a single open-market purchase in the recent window, and the only code that shows conviction, a P, is absent from the latest filings. The sale sizes are varied, which suggests routine portfolio management or tax planning, but the aggregate direction is unambiguous: she is selling, and she is selling in volume.
The two companies involved are not named in the recent data beyond UTHR, but the scale of the sell total across 2,346 trades indicates a sustained pattern over time. The November 4 cluster alone, with 24 separate S transactions, shows a deliberate and systematic approach to reducing her position. There is no recent buy activity to offset this, and the last purchase value of $863,947 is a fraction of the sell total. The data does not support any inference about motive, only that the sell side dominates her disclosed activity.
AI-assisted summary